US2017333353A1PendingUtilityA1
Bilayer tablet formulations
Est. expiryNov 13, 2029(~3.3 yrs left)· nominal 20-yr term from priority
A61P 5/50A61P 9/12A61P 3/10A61P 43/00A61P 9/10A61P 3/06A61P 27/02A61P 3/00A61P 3/04A61P 27/12A61P 25/00A61P 17/02A61P 13/12A61K 31/132A61K 31/7028A61K 31/7042A61K 31/155A61K 9/282A61K 31/70A61K 31/7034A61K 9/2054A61K 45/06A61K 31/403A61K 9/209A61K 31/7004
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
Claims
exact text as granted — not AI-modified1 . A bilayer tablet comprising: (1) a first layer wherein the first layer is a metformin hydrochloride extended release formulation; (2) a second layer wherein the second layer is a sodium dependent glucose transporter-2 inhibitor (SGLT2 inhibitor) formulation comprising dapagliflozin, dapagliflozin (S) propylene glycol hydrate, dapagliflozin (R) propylene glycol hydrate or canagliflozin; and (3) optionally a film coating comprising polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc that covers the first layer and the second layer.
2 - 32 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.